Breaking News
Ford Fathom: Everything We Know About The Sub-$30,000 Affordable EV Truck
Out of bullets, US will have to adjust and change security policy
Trump's top general seeks 'off-ramp' approach in Iran war amid 'limited' militar
Everything I Warned You About Just Happened... All in One Week
Top Tech News
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
Longeveron developing stem cell treatments for Frailty, Alzheimers and other aging diseases
Longeveron is a privately funded startup. The Longeveron-grown Mesenchymal Stem Cells (LMSCs) are multipotent stem cells.
Mesenchymal stem cells, or MSCs, are multipotent stromal cells that can differentiate into a variety of cell types, including: osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue). MSC have been found in organisms (in-vivo) and have been studied as well in tissue culture (in-vitro).
Nextbigfuture interviewed Dr. Joshua Hare, Longeveron Chief Science Officer. Dr. Joshua Hare co-founded Longeveron in 2014 utilizing intellectual property and technology exclusively licensed from the University of Miami, where he is also the founding Director of the university's Interdisciplinary Stem Cell Institute (ISCI).